
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9115015/publications.pdf Version: 2024-02-01



ΟΛΙΙΑ ΡΑΗΛΥ

#	Article	IF	CITATIONS
1	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet, The, 2016, 387, 760-769.	13.7	695
2	lsavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infectious Diseases, The, 2016, 16, 828-837.	9.1	528
3	Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infectious Diseases and Therapy, 2018, 7, 439-455.	4.0	313
4	BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clinical Microbiology and Infection, 2021, 27, 1652-1657.	6.0	263
5	Utilization of machine-learning models to accurately predict the risk for critical COVID-19. Internal and Emergency Medicine, 2020, 15, 1435-1443.	2.0	178
6	A unique megaplasmid contributes to stress tolerance and pathogenicity of an emergent <scp><i>S</i></scp> <i>almonella enterica</i> serovar Infantis strain. Environmental Microbiology, 2014, 16, 977-994.	3.8	172
7	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infectious Diseases, The. 2021. 21. e246-e257.	9.1	167
8	Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence. Clinical Infectious Diseases, 2018, 67, 649-656.	5.8	143
9	Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. Clinical Microbiology and Infection, 2021, 27, 1851-1855.	6.0	137
10	Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial. Clinical Infectious Diseases, 2019, 68, 1981-1989.	5.8	120
11	Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet, The, 2021, 397, 499-509.	13.7	119
12	BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response. Journal of Heart and Lung Transplantation, 2021, 40, 759-762.	0.6	112
13	Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel. Lancet Regional Health - Europe, The, 2021, 7, 100150.	5.6	101
14	Persistent Infections by Nontyphoidal <i>Salmonella</i> in Humans: Epidemiology and Genetics. Clinical Infectious Diseases, 2016, 62, 879-886.	5.8	98
15	Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood, 2022, 139, 678-685.	1.4	96
16	Horizontal Transfer of the Salmonella enterica Serovar Infantis Resistance and Virulence Plasmid pESI to the Gut Microbiota of Warm-Blooded Hosts. MBio, 2016, 7, .	4.1	92
17	Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Haematologica, 2022, 107, 625-634.	3.5	83
18	Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience. Journal of Heart and Lung Transplantation, 2022, 41, 148-157.	0.6	83

#	Article	IF	CITATIONS
19	Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma. EClinicalMedicine, 2020, 26, 100525.	7.1	64
20	Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk. JAMA Network Open, 2021, 4, e2122255.	5.9	64
21	BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study. EClinicalMedicine, 2021, 41, 101158.	7.1	64
22	Flagellin Is Required for Host Cell Invasion and Normal Salmonella Pathogenicity Island 1 Expression by Salmonella enterica Serovar Paratyphi A. Infection and Immunity, 2015, 83, 3355-3368.	2.2	57
23	The Stringent Response Regulator DksA Is Required for Salmonella enterica Serovar Typhimurium Growth in Minimal Medium, Motility, Biofilm Formation, and Intestinal Colonization. Infection and Immunity, 2016, 84, 375-384.	2.2	53
24	A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients. Clinical Infectious Diseases, 2020, 71, 2777-2786.	5.8	53
25	lsavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system. Medical Mycology, 2020, 58, 417-424.	0.7	48
26	Immunogenicity and safety of the BNT162b2 mRNA COVIDâ€19 vaccine in haematopoietic stem cell transplantation recipients. British Journal of Haematology, 2022, 196, 884-891.	2.5	48
27	Sink traps as the source of transmission of OXA-48–producing <i>Serratia marcescens</i> in an intensive care unit. Infection Control and Hospital Epidemiology, 2018, 39, 1307-1315.	1.8	46
28	Missed opportunities for earlier diagnosis of HIV in patients who presented with advanced HIV disease: a retrospective cohort study. BMJ Open, 2016, 6, e012721.	1.9	41
29	Humoral Response of Renal Transplant Recipients to the BNT162b2 SARS-CoV-2 mRNA Vaccine Using Both RBD IgG and Neutralizing Antibodies. Transplantation, 2021, 105, e234-e243.	1.0	39
30	Efficacy and safety of BNT162b2 vaccination inÂpatients with solid cancer receiving anticancer therapy – a single centre prospective study. European Journal of Cancer, 2021, 157, 124-131.	2.8	39
31	Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience. Journal of Infectious Diseases, 2022, 225, 785-792.	4.0	38
32	Genome Sequence of an Emerging Salmonella enterica Serovar Infantis and Genomic Comparison with Other S. Infantis Strains. Genome Biology and Evolution, 2020, 12, 223-228.	2.5	36
33	Immunogenicity and Adverse Effects of the 2â€Dose BNT162b2 Messenger RNA Vaccine Among Liver Transplantation Recipients. Liver Transplantation, 2022, 28, 215-223.	2.4	35
34	A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients. Journal of Hepatology, 2022, 77, 702-709.	3.7	35
35	Parental Staphylococcus aureus Carriage is Associated With Staphylococcal Carriage in Young Children. Pediatric Infectious Disease Journal, 2009, 28, 960-965.	2.0	33
36	Isavuconazole for treatment of rare invasive fungal diseases. Mycoses, 2018, 61, 518-533.	4.0	32

#	Article	IF	CITATIONS
37	Emergence of new variants of antibiotic resistance genomic islands among multidrugâ€resistantSalmonella entericain poultry. Environmental Microbiology, 2020, 22, 413-432.	3.8	30
38	The plasmid-encoded Ipf and Klf fimbriae display different expression and varying roles in the virulence of Salmonella enterica serovar Infantis in mouse vs. avian hosts. PLoS Pathogens, 2017, 13, e1006559.	4.7	30
39	Differences in Host Cell Invasion and Salmonella Pathogenicity Island 1 Expression between Salmonella enterica Serovar Paratyphi A and Nontyphoidal <i>S</i> . Typhimurium. Infection and Immunity, 2016, 84, 1150-1165.	2.2	29
40	Delayed diagnosis of colorectal sexually transmitted diseases due to their resemblance to inflammatory bowel diseases. International Journal of Infectious Diseases, 2018, 75, 34-38.	3.3	27
41	Automated processing of thermal imaging to detect COVID-19. Scientific Reports, 2021, 11, 17489.	3.3	25
42	lsavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. Mycoses, 2018, 61, 485-497.	4.0	24
43	Pathoadaptation of the passerine-associated Salmonella enterica serovar Typhimurium lineage to the avian host. PLoS Pathogens, 2021, 17, e1009451.	4.7	24
44	A peptide mimetic of the mycobacterial mannosylated lipoarabinomannan: characterization and potential applications. Journal of Medical Microbiology, 2007, 56, 579-586.	1.8	23
45	Measuring the effects of pneumococcal conjugate vaccine (PCV7) on Streptococcus pneumoniae carriage and antibiotic resistance: The Palestinian-Israeli Collaborative Research (PICR). Vaccine, 2015, 33, 1021-1026.	3.8	22
46	Feverlike Temperature is a Virulence Regulatory Cue Controlling the Motility and Host Cell Entry of Typhoidal Salmonella. Journal of Infectious Diseases, 2015, 212, 147-156.	4.0	22
47	Folate Levels in Patients Hospitalized with Coronavirus Disease 2019. Nutrients, 2021, 13, 812.	4.1	21
48	A machine learning model for predicting deterioration of COVID-19 inpatients. Scientific Reports, 2022, 12, 2630.	3.3	21
49	Clinical evaluation of early acquisition of Staphylococcus aureus carriage by newborns. International Journal of Infectious Diseases, 2017, 64, 9-14.	3.3	20
50	Hospitalized Patients With Severe Coronavirus Disease 2019 During the Omicron Wave in Israel: Benefits of a Fourth Vaccine Dose. Clinical Infectious Diseases, 2023, 76, e234-e239.	5.8	20
51	Population Screening Using Sewage Reveals Pan-Resistant Bacteria in Hospital and Community Samples. PLoS ONE, 2016, 11, e0164873.	2.5	19
52	Genetic divergence of Influenza A(H3N2) amino acid substitutions mark the beginning of the 2016–2017 winter season in Israel. Journal of Clinical Virology, 2017, 93, 71-75.	3.1	18
53	Rituximab identified as an independent risk factor for severe PJP: A case-control study. PLoS ONE, 2020, 15, e0239042.	2.5	18
54	The Impact of Carbapenem Resistance on Mortality in Patients With Klebsiella Pneumoniae Bloodstream Infection: An Individual Patient Data Meta-Analysis of 1952 Patients. Infectious Diseases and Therapy, 2021, 10, 541-558.	4.0	18

#	Article	IF	CITATIONS
55	Myocardial injury in hospitalized patients with COVID-19 infection—Risk factors and outcomes. PLoS ONE, 2021, 16, e0247800.	2.5	18
56	Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia. Leukemia, 2021, 35, 2727-2730.	7.2	18
57	Congenital cytomegalovirus infectiona question of screening. Israel Medical Association Journal, 2007, 9, 392-4.	0.1	17
58	BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients. Transplant International, 2022, 35, 10239.	1.6	17
59	Cytomegalovirus Retinitis in HIV-Negative Patients: A Practical Management Approach. Ophthalmology, 2015, 122, 866-868.e3.	5.2	16
60	The Typhi colonization factor (Tcf) is encoded by multiple non-typhoidal <i>Salmonella</i> serovars but exhibits a varying expression profile and interchanging contribution to intestinal colonization. Virulence, 2017, 8, 1791-1807.	4.4	16
61	Antibiotic treatment for invasive nonpregnancy-associated listeriosis and mortality: a retrospective cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 2243-2251.	2.9	15
62	Differences in the expression of SPI-1 genes pathogenicity and epidemiology between the emerging Salmonella enterica serovar Infantis and the model Salmonella enterica serovar Typhimurium. Journal of Infectious Diseases, 2019, 220, 1071-1081.	4.0	15
63	Integrative Analysis of Salmonellosis in Israel Reveals Association of Salmonella enterica Serovar 9,12:I,v:â [~] with Extraintestinal Infections, Dissemination of Endemic S. enterica Serovar Typhimurium DT104 Biotypes, and Severe Underreporting of Outbreaks. Journal of Clinical Microbiology, 2014, 52, 2078-2088.	3.9	14
64	Vivax Malaria Chemoprophylaxis: The Role of Atovaquone-Proguanil Compared to Other Options. Clinical Infectious Diseases, 2018, 66, 1751-1755.	5.8	14
65	Delftibactin-A, a Non-ribosomal Peptide With Broad Antimicrobial Activity. Frontiers in Microbiology, 2019, 10, 2377.	3.5	14
66	The emergence of a multidrug resistant Salmonella Muenchen in Israel is associated with horizontal acquisition of the epidemic pESI plasmid. Clinical Microbiology and Infection, 2022, 28, 1499.e7-1499.e14.	6.0	14
67	Staphylococcus aureus Colonization Induces Strain-Specific Suppression of Interleukin-17. Infection and Immunity, 2018, 86, .	2.2	13
68	Cat Scratch Disease Presenting as Fever of Unknown Origin Is a Unique Clinical Syndrome. Clinical Infectious Diseases, 2020, 71, 2818-2824.	5.8	12
69	Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection. Open Forum Infectious Diseases, 2020, 7, ofaa157.	0.9	12
70	Comparison of early effects of pneumococcal conjugate vaccines: PCV7, PCV10 and PCV13 on Streptococcus pneumoniae nasopharyngeal carriage in a population based study; The Palestinian-Israeli Collaborative Research (PICR). PLoS ONE, 2018, 13, e0206927.	2.5	11
71	The liver in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. European Journal of Gastroenterology and Hepatology, 2021, 33, e313-e319.	1.6	11
72	Piperacillin–tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen). BMJ Open, 2021, 11, e040210.	1.9	10

#	Article	IF	CITATIONS
73	Initial Effects of the National PCV7 Childhood Immunization Program on Adult Invasive Pneumococcal Disease in Israel. PLoS ONE, 2014, 9, e88406.	2.5	10
74	Coxiella burnetii Endocarditis and Aortic Vascular Graft Infection: An Underrecognized Disease. Annals of Thoracic Surgery, 2016, 101, 141-145.	1.3	9
75	Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole. Mycoses, 2018, 61, 868-876.	4.0	9
76	Emergency Department Triage in the Era of COVID-19: The Sheba Medical Center Experience. Israel Medical Association Journal, 2020, 22, 470-475.	0.1	9
77	Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II. Open Forum Infectious Diseases, 2019, 6, .	0.9	8
78	First report of a persistent oropharyngeal infection of type 2 vaccine-derived poliovirus (iVDPV2) in a primary immune deficient (PID) patient after eradication of wild type 2 poliovirus. International Journal of Infectious Diseases, 2019, 83, 40-43.	3.3	8
79	Group B Streptococcus serotypes associated with different clinical syndromes: Asymptomatic carriage in pregnant women, intrauterine fetal death, and early onset disease in the newborn. PLoS ONE, 2020, 15, e0244450.	2.5	8
80	The ancestral stringent response potentiator, DksA has been adapted throughout <i>Salmonella</i> evolution to orchestrate the expression of metabolic, motility, and virulence pathways. Gut Microbes, 2022, 14, 1997294.	9.8	8
81	Varied utilisation of health provision by Arab and Jewish residents in Israel. International Journal for Equity in Health, 2015, 14, 63.	3.5	7
82	Characteristics of Clinically Asymptomatic Patients with SARS-CoV-2 Infections, Case Series. Prehospital and Disaster Medicine, 2021, 36, 125-128.	1.3	7
83	Patterns and Predictors of <i>Staphylococcus aureus</i> Carriage during the First Year of Life: a Longitudinal Study. Journal of Clinical Microbiology, 2019, 57, .	3.9	6
84	Hospitalised patients with breakthrough COVID-19 following vaccination during two distinct waves in Israel, January to August 2021: a multicentre comparative cohort study. Eurosurveillance, 2022, 27, .	7.0	6
85	Genetic and Phenotypic Characterization of a Salmonella enterica serovar Enteritidis Emerging Strain with Superior Intra-macrophage Replication Phenotype. Frontiers in Microbiology, 2016, 7, 1468.	3.5	5
86	How many OPV rounds are required to stop wild polio virus circulation in a developed country? Lessons from the Israeli experience. Vaccine, 2016, 34, 299-301.	3.8	5
87	p53 in the mitochondria, as a trans-acting protein, provides error-correction activities during the incorporation of non-canonical dUTP into DNA. Oncotarget, 2016, 7, 73323-73336.	1.8	5
88	Waning humoral immune response to the BNT162b2 vaccine in heart transplant recipients over 6 months. American Journal of Transplantation, 2022, 22, 1931-1932.	4.7	5
89	Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours. European Journal of Cancer, 2022, 168, 51-55.	2.8	5
90	Cerebral phaeohyphomycosis in an immunocompetent patient: A case report and literature summary. Clinical Neurology and Neurosurgery, 2014, 124, 179-181.	1.4	4

#	Article	IF	CITATIONS
91	Establishing a COVID-19 treatment centre in Israel at the initial stage of the outbreak: challenges, responses and lessons learned. Emergency Medicine Journal, 2021, 38, 373-378.	1.0	4
92	Serological response to a third booster dose of BNT162b2 COVIDâ€19 vaccine among seronegative cancer patients. Cancer Reports, 2022, 5, .	1.4	4
93	Cytoplasmic p53 contributes to the removal of uracils misincorporated by HIV-1 reverse transcriptase. Biochemical and Biophysical Research Communications, 2018, 497, 804-810.	2.1	3
94	The impact of PCV7/13 on the distribution of carried pneumococcal serotypes and on pilus prevalence; 14Âyears of repeated cross-sectional surveillance. Vaccine, 2020, 38, 3591-3599.	3.8	3
95	Efficacy of Bezlotoxumab in Patients Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridium difficile Infection (CDI). Open Forum Infectious Diseases, 2016, 3, .	0.9	2
96	Underperformed and Underreported Testing for Persistent Oropharyngeal Poliovirus Infections in Primary Immune Deficient Patients—Risk for Reemergence of Polioviruses. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 326-333.	1.3	2
97	Hepatic Safety of Isavuconazole Compared With Voriconazole in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Complicated by Invasive Mold Disease: A Post-Hoc Analysis From the SECURE Study. Open Forum Infectious Diseases, 2016, 3, .	0.9	1
98	Primary Treatment of Invasive Mucormycosis (IM) with Isavuconazole (VITAL Study) or Amphotericin Formulations (FungiScopeâ,,¢): Case Matched Analysis. Blood, 2014, 124, 1151-1151.	1.4	1
99	Regional Advisory Board Position Statement on Optimal Pneumococcal Vaccination in Adults. Update to 2011 Consensus on Adult Pneumococcal Disease: Update on Optimal Pneumococcal Vaccination in Adults. Central European Journal of Public Health, 2013, 21, 233-236.	1.1	1
100	Letter of response to comment on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single centreÂprospective study. European Journal of Cancer, 2021, , .	2.8	1
101	Syphilis reinfection among people living with HIV. International Journal of STD and AIDS, 2022, 33, 416-417.	1.1	1
102	Healthcare-associated Pneumocystis jirovecii Pneumonia (PJP) Infection in HIV-negative Adults: a Multicenter Study. Israel Medical Association Journal, 2021, 23, 312-317.	0.1	1
103	Primary Versus Nonprimary West Nile Virus Infection: A Cohort Study. Journal of Infectious Diseases, 2016, 213, 755-761.	4.0	0
104	Participation and Life Satisfaction Among Women With Chronic Fatigue Syndrome (CFS). American Journal of Occupational Therapy, 2019, 73, 7311505115p1-7311505115p1.	0.3	0
105	BNT162b2 Vaccination Before Heart Transplantation. Transplantation, 2021, Publish Ahead of Print, .	1.0	0
106	Is now the time for the fourth BNT162b2 dose for residents of long-term care facilities?. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, , .	3.6	0